|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
D
|
|
INDICATIONS:
|
|
Infection, bone |
|
Infection, central nervous system |
|
Infection, intra- abdominal |
|
Infection, lower respiratory tract |
|
Infection, skin and skin structure |
|
Infection, urinary tract |
|
Meningitis |
|
Peritonitis |
|
Septicemia |
| |
|
|
SIDE EFFECTS:
|
|
azotemia |
|
cylindruria |
|
dizziness |
|
dysphonia |
|
hearing loss |
|
hyposthenuria |
|
injection site reaction |
|
myasthenia |
|
proteinuria |
|
pyuria |
|
renal tubular acidosis |
|
renal tubular necrosis |
|
tinnitus |
|
vertigo |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
botulism |
|
breast-feeding |
|
dehydration |
|
elderly |
|
hearing impairment |
|
myasthenia gravis |
|
neonates |
|
parkinsonism |
|
pregnancy |
|
renal disease |
|
|
ADULT DOSE:
|
|
Antibacterial(systemic)-Intramuscular or intravenous infusion, 0.75 mg to 1.25 mg (base) per kg of body weight every six hours; or 1 to 1.7 mg per kg of body weight every eight hours for seven to ten days or more. |
|
MAXIMUM ADULT DOSE:
|
|
Up to 8 mg (base) per kg of body weight daily in severe, life-threatening infections.
|
|
PEDIATRIC DOSE:
|
|
Antibacterial(systemic)-Intramuscular or intravenous infusion- Premature or full-term neonates up to 1 week of age:
Up to 2 mg (base) per kg of body weight every twelve to twenty-four hours.
Older infants and children:
-1.5 to 1.9 mg (base) per kg of body weight every six hours; or 2 to 2.5 mg per kg of body weight every eight to sixteen hours.
Note: The dosing interval of tobramycin in pediatric patients may vary from every four hours to every twenty-four hours, depending on the medical condition of the patient (cystic fibrosis, burns, renal dysfunction); serum levels must be monitored. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|